Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Cardiovasculares Carlos III (79)

2024

  1. Cholesterol lowering depletes atherosclerotic lesions of smooth muscle cell-derived fibromyocytes and chondromyocytes

    Nature Cardiovascular Research, Vol. 3, Núm. 2, pp. 203-220

  2. Circadian Effects on Vascular Immunopathologies

    Circulation Research, Vol. 134, Núm. 6, pp. 791-809

  3. From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline

    British Journal of Pharmacology

  4. Myeloid cells in vascular dementia and Alzheimer's disease: Possible therapeutic targets?

    British Journal of Pharmacology, Vol. 181, Núm. 6, pp. 777-798

  5. N-acetylcysteine during critical neurodevelopmental periods prevents behavioral and neurochemical deficits in the Poly I:C rat model of schizophrenia

    Translational Psychiatry, Vol. 14, Núm. 1

  6. Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

    British Journal of Pharmacology, Vol. 181, Núm. 6, pp. 760-776

  7. THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation

    Psychiatry Research, Vol. 331

  8. The role of gut microbiota in cerebrovascular disease and related dementia

    British Journal of Pharmacology, Vol. 181, Núm. 6, pp. 816-839

2023

  1. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120

  2. Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction

    Biomedicine and Pharmacotherapy, Vol. 158

  3. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  4. Defective hippocampal neurogenesis underlies cognitive impairment by carotid stenosis-induced cerebral hypoperfusion in mice

    Frontiers in Cellular Neuroscience, Vol. 17

  5. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  6. Ipsilesional Hippocampal GABA Is Elevated and Correlates With Cognitive Impairment and Maladaptive Neurogenesis After Cortical Stroke in Mice

    Stroke, Vol. 54, Núm. 10, pp. 2652-2665

  7. Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

    The Lancet Healthy Longevity, Vol. 4, Núm. 9, pp. e487-e498

  8. Neuroimaging Revealed Long-Lasting Glucose Metabolism Changes to Morphine Withdrawal in Rats Pretreated with the Cannabinoid Agonist CP-55,940 during Periadolescence

    European Neuropsychopharmacology, Vol. 69, pp. 60-76

  9. Neutrophil β1 adrenoceptor blockade blunts stroke-associated neuroinflammation

    British Journal of Pharmacology, Vol. 180, Núm. 4, pp. 459-478

  10. Novel Loss-of-Function KCNA5 Variants in Pulmonary Arterial Hypertension

    American Journal of Respiratory Cell and Molecular Biology, Vol. 69, Núm. 2, pp. 147-158

  11. Perinatal exposure to pesticides alters synaptic plasticity signaling and induces behavioral deficits associated with neurodevelopmental disorders

    Cell Biology and Toxicology, Vol. 39, Núm. 5, pp. 2089-2111

  12. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

    PLoS pathogens, Vol. 19, Núm. 1, pp. e1011063